The polarization of immune cells in the tumour environment by TGFβ (original) (raw)

• Massague, J. TGFβ in cancer. Cell 134, 215–230 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Wrzesinski, S. H., Wan, Y. Y. & Flavell, R. A. Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13, 5262–5270 (2007).
  Article CAS PubMed Google Scholar
• Padua, D. & Massague, J. Roles of TGFβ in metastasis. Cell Res. 19, 89–102 (2009).
  Article CAS PubMed Google Scholar
• Tian, M. & Schiemann, W. P. The TGF-β paradox in human cancer: an update. Future Oncol. 5, 259–271 (2009).
  Article CAS PubMed Google Scholar
• Bierie, B. & Moses, H. L. Transforming growth factor β (TGF-β) and inflammation in cancer. Cytokine Growth Factor Rev. 21, 49–59 (2010).
  Article CAS PubMed Google Scholar
• Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K. & Flavell, R. A. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24, 99–146 (2006).
  Article CAS PubMed Google Scholar
• Zou, W. & Restifo, N. P. TH17 cells in tumour immunity and immunotherapy. Nature Rev. Immunol. 10, 248–256 (2010).
  Article CAS Google Scholar
• Yang, Q., Goding, S. R., Hokland, M. E. & Basse, P. H. Antitumor activity of NK cells. Immunol. Res. 36, 13–25 (2006).
  Article PubMed Google Scholar
• Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ. Nature Immunol. 6, 600–607 (2005).
  Article CAS Google Scholar
• Rook, A. H. et al. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136, 3916–3920 (1986).
  CAS PubMed Google Scholar
• Wahl, S. M., Wen, J. & Moutsopoulos, N. M. The kiss of death: interrupted by NK-cell close encounters of another kind. Trends Immunol. 27, 161–164 (2006).
  Article CAS PubMed Google Scholar
• Trotta, R. et al. TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 181, 3784–3792 (2008).
  Article CAS PubMed Google Scholar
• Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nature Immunol. 9, 495–502 (2008).
  Article CAS Google Scholar
• Castriconi, R. et al. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl Acad. Sci. USA 100, 4120–4125 (2003).
  Article CAS PubMed Central PubMed Google Scholar
• Crane, C. A. et al. TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro. Oncol. 12, 7–13 (2010).
  Article CAS PubMed Google Scholar
• Lee, J.-C., Lee, K.-M., Kim, D.-W. & Heo, D. S. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172, 7335–7340 (2004).
  Article CAS PubMed Google Scholar
• Kopp, H. G., Placke, T. & Salih, H. R. Platelet-derived transforming growth factor-β down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69, 7775–7783 (2009).
  Article CAS PubMed Google Scholar
• Li, H., Han, Y., Guo, Q., Zhang, M. & Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J. Immunol. 182, 240–249 (2009).
  Article CAS PubMed Google Scholar
• Steinman, R. M. & Banchereau, J. Taking dendritic cells into medicine. Nature 449, 419–426 (2007).
  Article CAS PubMed Google Scholar
• Ferlazzo, G. & Munz, C. Dendritic cell interactions with NK cells from different tissues. J. Clin. Immunol. 29, 265–273 (2009).
  Article CAS PubMed Google Scholar
• Dhodapkar, M. V., Dhodapkar, K. M. & Palucka, A. K. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 15, 39–50 (2008).
  Article CAS PubMed Google Scholar
• Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255–258 (2001).
  Article CAS PubMed Google Scholar
• Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769–779 (2001).
  Article CAS PubMed Central PubMed Google Scholar
• Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685–711 (2003).
  Article CAS PubMed Google Scholar
• Yamazaki, S. & Steinman, R. M. Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells. J. Dermatol. Sci. 54, 69–75 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• Kortylewski, M. et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114–123 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• Ito, M. et al. Tumor-derived TGFβ-1 induces dendritic cell apoptosis in the sentinel lymph node. J. Immunol. 176, 5637–5643 (2006).
  Article CAS PubMed Google Scholar
• Weber, F. et al. Transforming growth factor-β1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. Cancer Immunol. Immunother. 54, 898–906 (2005).
  Article CAS PubMed Google Scholar
• Halliday, G. M. & Le, S. Transforming growth factor-β produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. Int. Immunol. 13, 1147–1154 (2001).
  Article CAS PubMed Google Scholar
• Bekeredjian-Ding, I. et al. Tumour-derived prostaglandin E and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α. Immunology 128, 439–450 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• Zhang, X. et al. CD4−8− dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity. J. Immunol. 175, 2931–2937 (2005).
  Article CAS PubMed Google Scholar
• Roncarolo, M. G., Levings, M. K. & Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193, F5–F9 (2001).
  Article CAS PubMed Central PubMed Google Scholar
• Yamazaki, S. et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235–247 (2003).
  Article CAS PubMed Central PubMed Google Scholar
• Tarbell, K. V., Yamazaki, S., Olson, K., Toy, P. & Steinman, R. M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199, 1467–1477 (2004).
  Article CAS PubMed Central PubMed Google Scholar
• Banerjee, D. K., Dhodapkar, M. V., Matayeva, E., Steinman, R. M. & Dhodapkar, K. M. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108, 2655–2661 (2006).
  Article CAS PubMed Central PubMed Google Scholar
• Chung, D. J. et al. Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114, 555–563 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• Luo, X. et al. Dendritic cells with TGF-β1 differentiate naive CD4+CD25− T cells into islet-protective Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA 104, 2821–2826 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Levings, M. K., Bacchetta, R., Schulz, U. & Roncarolo, M. G. The role of IL-10 and TGF-β in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 129, 263–276 (2002).
  Article CAS PubMed Google Scholar
• Ghiringhelli, F. et al. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202, 919–929 (2005).
  Article CAS PubMed Central PubMed Google Scholar
• Liu, V. C. et al. Tumor evasion of the immune system by converting CD4+CD25− T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-β. J. Immunol. 178, 2883–2892 (2007).
  Article CAS PubMed Google Scholar
• Yamazaki, S. et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J. Immunol. 181, 6923–6933 (2008).
  Article CAS PubMed Google Scholar
• Dumitriu, I. E., Dunbar, D. R., Howie, S. E., Sethi, T. & Gregory, C. D. Human dendritic cells produce TGF-β 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 182, 2795–2807 (2009).
  Article CAS PubMed Google Scholar
• Mantovani, A., Sica, A., Allavena, P., Garlanda, C. & Locati, M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 70, 325–330 (2009).
  Article CAS PubMed Google Scholar
• Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin's Lymphoma. N. Engl. J. Med. 362, 875–885 (2010).
  Article CAS PubMed Central PubMed Google Scholar
• Martinez, F. O., Helming, L. & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451–483 (2009).
  Article CAS PubMed Google Scholar
• Sica, A. et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349–355 (2008).
  Article CAS PubMed Google Scholar
• Byrne, S. N., Knox, M. C. & Halliday, G. M. TGFβ is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol. Cell Biol. 86, 92–97 (2008).
  Article CAS PubMed Google Scholar
• Biswas, S. K. et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). Blood 107, 2112–2122 (2006).
  Article CAS PubMed Google Scholar
• Saccani, A. et al. p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66, 11432–11440 (2006).
  Article CAS PubMed Google Scholar
• Porta, C. et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB. Proc. Natl Acad. Sci. USA 106, 14978–14983 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231–237 (2010).
  Article CAS PubMed Google Scholar
• Torroella-Kouri, M. et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 69, 4800–4809 (2009). This study shows that TGFβ and prostaglandin E 2 individually and additively downregulate NF-κB and C/EBP expression in a unique less-differentiated macrophage subpopulation.
  Article CAS PubMed Google Scholar
• Umemura, N. et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol. 83, 1136–1144 (2008).
  Article CAS PubMed Google Scholar
• Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R. K. & Kitani, A. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nature Med. 12, 99–106 (2006).
  Article CAS PubMed Google Scholar
• Gratchev, A. et al. Activation of a TGF-β-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-β receptor II. J. Immunol. 180, 6553–6565 (2008).
  Article CAS PubMed Google Scholar
• Allen, S. S. et al. Altered inflammatory responses following transforming growth factor-β neutralization in experimental guinea pig tuberculous pleurisy. Tuberculosis (Edinb.) 88, 430–436 (2008).
  Article CAS Google Scholar
• Smith, W. B. et al. Transforming growth factor-β1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J. Immunol. 157, 360–368 (1996).
  CAS PubMed Google Scholar
• Shen, L. et al. Inhibition of human neutrophil degranulation by transforming growth factor-β1. Clin. Exp. Immunol. 149, 155–161 (2007).
  Article CAS PubMed Central PubMed Google Scholar
• Di Carlo, E. et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339–345 (2001).
  Article CAS PubMed Google Scholar
• Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell 16, 183–194 (2009). This study provides the first evidence that TGFβ controls pro-tumour versus antitumour immune responses by polarizing neutrophil subpopulations to N1 or N2 phenotypes in the tumour microenvironment.
  Article CAS PubMed Central PubMed Google Scholar
• Nozawa, H., Chiu, C. & Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103, 12493–12498 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Pekarek, L. A., Starr, B. A., Toledano, A. Y. & Schreiber, H. Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181, 435–440 (1995).
  Article CAS PubMed Google Scholar
• Tazawa, H. et al. Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am. J. Pathol. 163, 2221–2232 (2003).
  Article CAS PubMed Central PubMed Google Scholar
• Colombo, M. P., Modesti, A., Parmiani, G. & Forni, G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte–T-lymphocyte cross-talk. Cancer Res. 52, 4853–4857 (1992).
  CAS PubMed Google Scholar
• Hicks, A. M. et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc. Natl Acad. Sci. USA 103, 7753–7758 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Stoppacciaro, A. et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte–T cell cooperation and T cell-produced interferon γ. J. Exp. Med. 178, 151–161 (1993).
  Article CAS PubMed Google Scholar
• Schumacher, K., Haensch, W., Roefzaad, C. & Schlag, P. M. Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res. 61, 3932–3936 (2001).
  CAS PubMed Google Scholar
• Nakano, O. et al. Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132–5136 (2001).
  CAS PubMed Google Scholar
• Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
  CAS PubMed Google Scholar
• Gao, Q. et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25, 2586–2593 (2007).
  Article PubMed Google Scholar
• Thomas, D. A. & Massague, J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369–380 (2005).
  Article CAS PubMed Google Scholar
• Zhang, Q. et al. Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle. Mol. Cancer Ther. 5, 1733–1743 (2006).
  Article CAS PubMed Google Scholar
• Franciszkiewicz, K. et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res. 69, 6249–6255 (2009).
  Article CAS PubMed Google Scholar
• Gorelik, L. & Flavell, R. A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171–181 (2000).
  Article CAS PubMed Google Scholar
• Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118–1122 (2001).
  Article CAS PubMed Google Scholar
• Zhang, Q. et al. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65, 1761–1769 (2005).
  Article CAS PubMed Google Scholar
• Wang, L. et al. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor β-insensitive CD8+ T cells. Clin. Cancer Res. 16, 164–173 (2010).
  Article CAS PubMed Google Scholar
• Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway. Nature Immunol. 1, 515–520 (2000).
  Article CAS Google Scholar
• Terabe, M. et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198, 1741–1752 (2003).
  Article CAS PubMed Central PubMed Google Scholar
• Nam, J. S. et al. An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835–3843 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Wallace, A. et al. Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966–3974 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Takaku, S. et al. Blockade of TGF-β enhances tumor vaccine efficacy mediated by CD8+ T cells. Int. J. Cancer 126, 1666–1674 (2010).
  CAS PubMed Central PubMed Google Scholar
• Terabe, M. et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-β monoclonal antibody. Clin. Cancer Res. 15, 6560–6569 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• Ueda, R. et al. Systemic inhibition of transforming growth factor-β in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin. Cancer Res. 15, 6551–6559 (2009). References 82–84 show that the combination of a TGFβ-specific antibody with a vaccine results in a synergistic improvement in the inhibition of tumour growth that is mediated by increased number and activity of CD8+ T cells.
  Article CAS PubMed Central PubMed Google Scholar
• Sanjabi, S., Mosaheb, M. M. & Flavell, R. A. Opposing effects of TGF-β and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 31, 131–144 (2009). This study shows the ability of TGFβ to promote apoptosis of effector CD8+ T cells under immunogenic conditions, such as vaccination.
  Article CAS PubMed Central PubMed Google Scholar
• Ahmadzadeh, M. & Rosenberg, S. A. TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J. Immunol. 174, 5215–5223 (2005).
  Article CAS PubMed Google Scholar
• di Bari, M. G. et al. TGF-β modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. Cancer Immunol. Immunother. 58, 1809–1818 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• Nam, J. S. et al. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 68, 3915–3923 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Hinrichs, C. S. et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114, 596–599 (2009). This study shows that IL-17-producing CD8+ T cells mediate tumour regression and persist longer than normal CD8+ T cells after adoptive transfer in tumour-bearing mice.
• Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362–373 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787–798 (2009). References 90 and 91 provide compelling evidence comparing the therapeutic potential of adoptively transferred T H cell subpopulations and show that T H 17-polarized cells are the most effective in tumour eradication.
  Article CAS PubMed Central PubMed Google Scholar
• Li, M. O. & Flavell, R. A. TGF-β: a master of all T cell trades. Cell 134, 392–404 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Li, X. F. et al. Transforming growth factor-β (TGF-β)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-β and a progressive increase in TGF-β susceptibility of anti-tumor CD4+ T cell function. Jpn. J. Cancer Res. 84, 315–325 (1993).
  Article CAS PubMed Central PubMed Google Scholar
• Maeda, H. & Shiraishi, A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 156, 73–78 (1996).
  CAS PubMed Google Scholar
• Knutson, K. L. & Disis, M. L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54, 721–728 (2005).
  Article CAS PubMed Google Scholar
• Muranski, P. & Restifo, N. P. Adoptive immunotherapy of cancer using CD4+ T cells. Curr. Opin. Immunol. 21, 200–208 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• Gao, F. G. et al. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res. 62, 6438–6441 (2002).
  CAS PubMed Google Scholar
• Perez-Diez, A. et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346–5354 (2007). This report shows the potential of CD4+ T cells for tumour elimination even in the absence of CD8+ T cells and independent of MHC class II expression by tumour cells.
  Article CAS PubMed Central PubMed Google Scholar
• Martin-Orozco, N. & Dong, C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr. Opin. Invest. Drugs 10, 543–549 (2009).
  CAS Google Scholar
• Murugaiyan, G. & Saha, B. Protumor vs antitumor functions of IL-17. J. Immunol. 183, 4169–4175 (2009).
  Article CAS PubMed Google Scholar
• Miyahara, Y. et al. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc. Natl Acad. Sci. USA 105, 15505–15510 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Su, X. et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 184, 1630–1641 (2010).
  Article CAS PubMed Google Scholar
• Nurieva, R., Yang, X. O., Chung, Y. & Dong, C. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J. Immunol. 182, 2565–2568 (2009).
  Article CAS PubMed Google Scholar
• Xie, Y. et al. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207, 651–667 (2010). This report shows for the first time the potential use of naive CD4+ T cells in transfer experiments to induce potent antitumour immunity in vivo .
  Article CAS PubMed Central PubMed Google Scholar
• Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).
  Article CAS PubMed Central PubMed Google Scholar
• Kryczek, I. et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178, 6730–6733 (2007).
  Article CAS PubMed Google Scholar
• Pellegrini, M. et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nature Med. 15, 528–536 (2009).
  Article CAS PubMed Google Scholar
• Curotto de Lafaille, M. A. & Lafaille, J. J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30, 626–635 (2009).
  Article CAS PubMed Google Scholar
• Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942–949 (2004).
  Article CAS PubMed Google Scholar
• Merlo, A. et al. FOXP3 expression and overall survival in breast cancer. J. Clin. Oncol. 27, 1746–1752 (2009).
  Article CAS PubMed Google Scholar
• Moo-Young, T. A. et al. Tumor-derived TGF-β mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J. Immunother. 32, 12–21 (2009). In this study, TGFβ derived from the tumour promotes in situ T Reg cell differentiation, showing a mechanism of immune surveillance.
  Article CAS PubMed Google Scholar
• Beyer, M. & Schultze, J. L. Regulatory T cells in cancer. Blood 108, 804–811 (2006).
  Article CAS PubMed Google Scholar
• Solinas, G., Germano, G., Mantovani, A. & Allavena, P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86, 1065–1073 (2009).
  Article CAS PubMed Google Scholar
• Han, Y., Guo, Q., Zhang, M., Chen, Z. & Cao, X. CD69+ CD4+ CD25− T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1. J. Immunol. 182, 111–120 (2009).
  Article CAS PubMed Google Scholar
• Chen, W. et al. Conversion of Peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875–1886 (2003).
  CAS PubMed Central PubMed Google Scholar
• Fantini, M. C. et al. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25− T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172, 5149–5153 (2004).
  Article CAS PubMed Google Scholar
• Petrausch, U. et al. Disruption of TGF-β signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J. Immunol. 183, 3682–3689 (2009).
  Article CAS PubMed Google Scholar
• Niederkorn, J. Y. Emerging concepts in CD8+ T regulatory cells. Curr. Opin. Immunol. 20, 327–331 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Kapp, J. A. & Bucy, R. P. CD8+ suppressor T cells resurrected. Hum. Immunol. 69, 715–720 (2008).
  Article CAS PubMed Google Scholar
• Jarnicki, A. G., Lysaght, J., Todryk, S. & Mills, K. H. Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177, 896–904 (2006).
  Article CAS PubMed Google Scholar
• Shafer-Weaver, K. A. et al. Cutting edge: tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J. Immunol. 183, 4848–4852 (2009).
  Article CAS PubMed Google Scholar
• Chaput, N. et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58, 520–529 (2009).
  Article CAS PubMed Google Scholar
• Kiniwa, Y. et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13, 6947–6958 (2007).
  Article CAS PubMed Google Scholar
• Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. & Kaer, L. V. NKT cells: what's in a name? Nature Rev. Immunol. 4, 231–237 (2004).
  Article CAS Google Scholar
• Berzofsky, J. & Terabe, M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol. Immunother. 57, 1679–1683 (2008).
  Article CAS PubMed Google Scholar
• Berzofsky, J. A. & Terabe, M. The contrasting roles of NKT cells in tumor immunity. Curr. Mol. Med. 9, 667–672 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• van der Vliet, H. J. et al. Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J. Immunol. 180, 7287–7293 (2008).
  Article CAS PubMed Google Scholar
• Calvo-Aller, E. et al. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-β receptor I kinase. ASCO Annual Meeting. J. Clin. Oncol. Abstr. 26, 14554 (2008).
  Article Google Scholar
• Fakhrai, H. et al. Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 13, 1052–1060 (2006).
  Article CAS PubMed Google Scholar
• Nemunaitis, J. et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24, 4721–4730 (2006).
  Article CAS PubMed Google Scholar
• Nemunaitis, J. et al. Phase II trial of belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 16, 620–624 (2009). One of the few recent studies evaluating TGFβ blockade in humans; there are several limitations regarding design of trial and true 'efficacy' of this approach.
  Article CAS PubMed Google Scholar
• Schlingensiepen, K.-H. et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129–139 (2006).
  Article CAS PubMed Google Scholar
• Schlingensiepen, R. et al. Intracerebral and intrathecal infusion of the TGF-β2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15, 94–104 (2005).
  Article CAS PubMed Google Scholar
• Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M. & Chen, L. Immunostimulatory monoclonal antibodies for cancer therapy. Nature Rev. Cancer 7, 95–106 (2007).
  Article CAS Google Scholar
• O'Garra, A., Stockinger, B. & Veldhoen, M. Differentiation of human TH-17 cells does require TGF-β! Nature Immunol. 9, 588–590 (2008).
  Article CAS Google Scholar
• Schreiber, T. H., Deyev, V. V., Rosenblatt, J. D. & Podack, E. R. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res. 69, 2026–2033 (2009).
  Article CAS PubMed Central PubMed Google Scholar
• Levy, L. & Hill, C. S. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41–58 (2006).
  Article CAS PubMed Google Scholar
• Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nature Rev. Cancer 3, 807–821 (2003).
  Article CAS Google Scholar
• Nagaraj, N. S. & Datta, P. K. Targeting the transforming growth factor-β signaling pathway in human cancer. Expert Opin. Investig. Drugs 19, 77–91 (2010).
  Article CAS PubMed Google Scholar
• Wei, S. et al. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor β. Cancer Res. 68, 5432–5438 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Schlingensiepen, K.-H. et al. The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies. J. Clin. Immunol. 22, 3132 (2004).
  Google Scholar
• Khaw, P. et al. A phase III study of subconjunctival human anti-transforming growth factor β(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 114, 1822–1830 (2007).
  Article PubMed Google Scholar
• Benigni, A. et al. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14, 1816–1824 (2003).
  Article CAS PubMed Google Scholar
• Morris, J. C. et al. Phase I/II study of GC1008: A human anti-transforming growth factor-β (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). ASCO Annual Meeting. J. Clin. Oncol. Abstr. 26, 9028 (2008).
  Article Google Scholar
• Nam, J.-S. et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor β in a mouse model of breast cancer. Cancer Res. 66, 6327–6335 (2006).
  Article CAS PubMed Central PubMed Google Scholar
• Zhong, Z. et al. Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16, 1191–1205 (2010). The newest study evaluating an antibody specific for TGFβRII, which shows antitumour responses against mouse mammary and colon cancer cell lines by increasing CTL and NK cell activity while decreasing the number of T Reg cells and MDSCs in mice treated with these antibodies.
  Article CAS PubMed Google Scholar
• Kano, M. R. et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl Acad. Sci. USA 104, 3460–3465 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Scott Sawyer, J. et al. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4_H_-pyrrolo[1,2-_b_]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorg. Med. Chem. Lett. 14, 3581–3584 (2004).
  Article CAS PubMed Google Scholar
• Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65–74 (2002).
  Article CAS PubMed Google Scholar
• Saunier, E. F. & Akhurst, R. J. TGFβ inhibition for cancer therapy. Curr. Cancer Drug Targets. 6, 565–578 (2006).
  Article CAS PubMed Google Scholar
• Hayashi, T. et al. Transforming growth factor β receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res. 10, 7540–7546 (2004).
  Article CAS PubMed Google Scholar
• Uhl, M. et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954–7961 (2004).
  Article CAS PubMed Google Scholar
• Ehata, S. et al. Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 98, 127–133 (2007).
  Article CAS PubMed Google Scholar
• Kim, S. et al. Systemic blockade of transforming growth factor-β signaling augments the efficacy of immunogene therapy. Cancer Res. 68, 10247–10256 (2008). Recent evidence of successful combination therapy using TGFβ-blocking reagents.
  Article CAS PubMed Central PubMed Google Scholar
• Suzuki, E. et al. A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 67, 2351–2359 (2007).
  Article CAS PubMed Google Scholar
• Qiqi, C., Sang Kyun, L., Bryan, Z. & Hoffmann, F. M. Selective inhibition of TGF-β responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene 24, 3864–3874 (2005).
  Article CAS Google Scholar
• Llopiz, D. et al. Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy. Int. J. Cancer 125, 2614–2623 (2009).
  Article CAS PubMed Google Scholar
• Yang, Y.-A. et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607–1615 (2002).
  Article CAS PubMed Central PubMed Google Scholar
• Fujita, T. et al. Inhibition of transforming growth factor-β-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 69, 5142–5150 (2009).
  Article CAS PubMed Google Scholar
• Foster, A. E. et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. J. Immunother. 31, 500–505 (2008).
  Article CAS PubMed Central PubMed Google Scholar
• Melisi, D. et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer. Ther. 7, 829–840 (2008).
  Article CAS PubMed Central PubMed Google Scholar